Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer telehealth. Confidential tips can be sent on Signal at palmer.01.Peptides are poised to go mainstream with this week’s launches from telehealth companies Hims & Hers and Noom, both of which announced they will be offering prescriptions for eligible patients. Synthetic peptides are a broad category of short-chain amino acids. Initially popular among bodybuilders, certain drugs in the class have gained traction among a broad swath of people looking to optimize their health — whether to build muscle, feel more energetic, increase libido, or recover from injuries. But many compounded peptides that are marketed to consumers are experimental. They have not been approved by the Food and Drug Administration, nor do they have randomized controlled trials showing their safety and efficacy in humans. The Department of Health and Human Services, however, has foregrounded the drugs under secretary Robert F. Kennedy Jr. (an avowed peptide enthusiast). While peptide prescriptions were already offered by smaller telehealth companies, Hims (with a market cap of more than $3.5 billion) and Noom (a private company valued at $3.7 billion) are two of the industry’s dominant players, making the announcements a pivotal moment for peptides in the United States. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
STAT+: Peptide market poised to explode with new Hims and Noom launches
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.